KURA vs AGIO

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus 25. 2% for Kura Oncology, Inc. (KURA). Analysts rate Kura Oncology, Inc. (KURA) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Agios Pharmaceuticals, Inc.

(AGIO) delivered a total return of -51. 0%, compared to -61. 8% for Kura Oncology, Inc. (KURA). Over 10 years, the gap is even starker: KURA returned +245. 8% versus AGIO's -38. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc.

(AGIO) is the lower-risk stock at 1. 12β versus Kura Oncology, Inc. 's 1. 66β — meaning KURA is approximately 49% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 5% versus 6% for Kura Oncology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus 25. 2% for Kura Oncology, Inc. (KURA). On earnings-per-share growth, the picture is similar: Kura Oncology, Inc. grew EPS -57. 4% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kura Oncology, Inc.

(KURA) is the more profitable company, earning -412. 9% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps -412. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KURA leads at -449. 9% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — KURA leads at 99. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Kura Oncology, Inc. (KURA) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AGIO: -38. 1%, KURA: +245. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.